Every S-1 that DROR ORTHO-DESIGN INC (DROR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow DROR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DROR filings page.
Dror Ortho-Design, Inc. (DROR) has filed Amendment No. 4 to its Form S-1 for a firm-commitment underwritten offering of 3,636,364 shares of common stock at an assumed price of $4.13 per share, with an equal alternative of Prefunded Warrants, plus 545,455 over-allotment shares and 254,545 Underwriter Warrants. The company expects to complete a 1-for-550 reverse stock split prior to or upon effectiveness and will only proceed if its common stock is approved for listing on the Nasdaq Capital Market.
On a post-split basis, shares outstanding are expected to be 1,776,358 before and 5,412,722 after the offering (assuming no Prefunded Warrants and no warrant exercises). Estimated net proceeds are about $13 million (or $15 million with full over-allotment), to be used primarily for working capital and general corporate purposes. Dror is a development-stage Israel-based orthodontic device company with its AI-based ZSmile Platform cleared as a Class II medical device via FDA 510(k), but it currently generates no revenue and reported net losses of $2.5 million in 2025 and $5.8 million in 2024.
The independent auditor expressed substantial doubt about Dror’s ability to continue as a going concern, citing recurring losses and cash of about $228 thousand as of December 31, 2025. The company discloses that it will need additional capital, faces significant geopolitical and macroeconomic risks due to operating entirely in Israel, and competes against large established clear-aligner companies in a market projected to grow from $8.3 billion in 2025 to $56.8 billion by 2033.
Dror Ortho-Design, Inc. is registering up to 3,636,364 shares of common stock, 3,636,364 prefunded warrants, 254,545 underwriter warrants, and 3,890,909 underlying shares in a firm-commitment public offering tied to a planned Nasdaq Capital Market listing.
The assumed public offering price is $4.13 per share, with a 30‑day over-allotment option for 545,455 additional shares. A 1‑for‑550 reverse stock split will occur prior to effectiveness. Net proceeds are estimated at about $13 million, or $15 million with full over-allotment, mainly for working capital and general corporate purposes.
On a post‑split basis, common stock outstanding is expected to rise from 1,776,358 to 5,412,722 shares, assuming no prefunded warrants are sold and no underwriter warrants are exercised. The company has a going concern warning, cash of about $228 thousand as of December 31, 2025, and plans to commercialize its FDA 510(k)‑cleared ZSmile clear-aligner platform while operating amid elevated geopolitical and macroeconomic risks.
Dror Ortho-Design, Inc. is registering 2,020,203 shares of common stock, related prefunded warrants and underwriter warrants in a firm-commitment public offering conditional on NYSE American listing approval. The company expects net proceeds of about $8.9 million, or $10.3 million with full over-allotment, mainly for working capital and general corporate purposes.
Dror plans a 1-for-450 reverse stock split before or upon effectiveness, which would raise post-split shares outstanding from 2,171,104 to about 4,191,307 if all common shares are sold and no prefunded or underwriter warrants are exercised. The business is pre-revenue, developing an AI-based orthodontic platform and has incurred recurring losses, with only $549 thousand of cash at December 31, 2024 and $240,362 at September 30, 2025, leading auditors and management to express substantial doubt about its ability to continue as a going concern without additional capital.
Operations are concentrated in Israel, exposing Dror to significant geopolitical and macroeconomic risks, including recent regional conflicts, potential supply chain disruptions and staffing impacts. The company also faces extensive regulatory, market-acceptance and competitive risks as it seeks FDA 510(k) clearance for its updated platform and attempts to enter a clear-aligner market dominated by large, established players.